2017 Edition of Mass Spectra of Designer Drugs
- Published: Mar 21, 2017
Available now from Wiley and Wiley-VCH, the 2017 edition of Mass Spectra of Designer Drugs
The rapid development of designer drugs poses serious challenges to current policies, procedures, and methods for detection and identification of these substances.
Mass Spectra of Designer Drugs was developed to support forensics and toxicology labs in combatting this global health epidemic and is the largest collection of chemical signatures of novel psychoactive substances (NPS) and drugs of abuse in the world.
The 2017 edition features:
- Over 25,100 mass spectra – an addition of more than 1,600 since 2016
- Over 19,600 unique compounds predominantly classified as novel psychoactive substances (NPS)
- Over 800 new, unique compounds in over 30 different classification groups such as, fentanyles, synthetic cannabinoids, and benzodiazepines.
With an average quality index per spectrum of 947.8 and 15,949 kovats retention indices this spectral database provides comprehensive data on the most up-to-date list of novel psychoactive substances.
To find out more, request a quote or arrange a demo, please contact us http://news.wiley.com/DatabaseDemo.